DNA Assay May Distinguish Responses to mRCC Immunotherapy
The TARDIS assay could be used to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
International Kidney Cancer Symposium
Efficacy, Safety of Triple Combo for Advanced Kidney Cancer Probed
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
High-dose Interleukin-2 Continues To Be Safe, Effective First-Line mRCC Treatment
High-dose interleukin-2 (HD IL-2) continues to have a favorable safety profile compared with data in the original package insert.
Study Assessing Dalantercept Plus Axitinib for Advanced Clear Cell RCC
Researchers are enrolling patients for part 2 of a phase 2 trial to compare dalantercept plus axitinib for treatment of renal cell carcinoma (RCC).
Study Supports Standard Sequence of Sunitinib Followed by Everolimus in mRCC
Final overall survival results of the RECORD-3 trial are consistent with results and support the standard sequence of sunitinib followed by everolimus.
Axitinib Treatment May Result in Higher Drug Costs Than Everolimus for Advanced RCC
Axitinib treatment may result in higher drug costs compared with everolimus.
Adding TRC105 to Axitinib May Improve PFS for Clear Cell RCC
A phase 2 trial is enrolling patients with renal cell carcinoma (mRCC) to compare the combination of axitinib plus TRC105 with axitinib alone.
Alternative Axitinib Dose Escalation Schema May Improve Tolerability in mRCC
Axitinib initiated at 5 mg twice daily resulted in toleration of higher daily doses with sustained efficacy in patients with metastatic renal cell carcinoma (mRCC).
Similar Outcomes with Everolimus as Second Targeted Therapy for aRCC After Pazopanib or Sunitinib/Sorafenib
Clinical outcomes with everolimus as a second targeted therapy were not significantly different in advanced renal cell carcinoma (aRCC).
Almost Half of All Patients With mRCC Defer Frontline Systemic Therapy
A large percentage of real-world patients with metastatic renal cell carcinoma (mRCC) initially deferred systemic therapy.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in International Kidney Cancer Symposium (IKCS) 2015
Loading... 
Loading...